Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9808291 | 0.85 | KCNH2 (0.57) | KCNH2KCNA3CA12CA1CA2 | |
| SCHEMBL1790840 | 0.81 | KCNH2 (0.53) | KCNH2KCNA3CA12CA1CA2 | |
| Diphenylether SCHEMBL10632533 | 0.79 | LTA4H (0.57) | KCNH2KCNA3CA12CA1CA2 | |
| SCHEMBL11201791 | 0.78 | GRM5 (0.50) | KCNH2ALDH1A1DRD2DRD4DRD3 | |
| SCHEMBL10534041 | 0.78 | EPHX2 (0.40) | DRD2DRD4DRD3CYP2C19TDP1 | |
| SCHEMBL1618118 | 0.77 | KCNH2 (0.50) | KCNH2KCNA3CA12CA1CA2 | |
| SCHEMBL9338770 | 0.77 | KCNH2 (0.55) | KCNH2KCNA3CA12CA1CA2 | |
| SCHEMBL10571938 | 0.77 | KCNH2 (0.50) | KCNH2KCNA3CA12CA1CA2 | |
| SCHEMBL10246513 | 0.77 | KCNH2 (0.50) | KCNH2KCNA3CA12CA1CA2 | |
| SCHEMBL11483215 | 0.77 | KCNH2 (0.50) | KCNH2KCNA3CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700799-B2 | Method for producing (2-formyl-1-alkenyl) cyclopropane compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20090137839-A1 | METHOD FOR PRODUCING (2-FORMYL-1-ALKENYL) CYCLOPROPANE COMPOUND | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7498459-B2 | Method for producing (1-alkenyl)cyclopropane compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20070197818-A1 | Method for producing (1-alkenyl) cyclopropane compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-08-23 | — | — | US | disclosed |
| EP-1728781-A1 | PROCESS FOR PRODUCTION OF (1-ALKENYL)CYCLOPROPANES | Sumitomo Chemical Company, Limited (JP) | 2006-12-06 | — | — | EP | disclosed |
| US-6323235-B1 | CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS AND ENZYME INHIBITORS | OHTAKE ATSUSHI (JP) | 2001-11-27 | — | — | US | disclosed |
| US-6043264-A | A THROMBOXANE A2 RECEPTOR ANTAGONIST FOR TREATING HYPERTENSION, THROMBOSIS, ISCHEMIC HEART DISEASES, CIRCULATORY DISEASES, ARTERIOSCLEROSIS, PLATELET FUNCTION DISORDER, HYPERLIPIDEMIA, NEPHRITIS OR ASTHMA | TORAY INDUSTRIES, INC. (JP) | 2000-03-28 | — | — | US | disclosed |
| EP-0751126-A1 | BENZENE-FUSED HETEROCYCLIC DERIVATIVE AND USE OF THE SAME | TORAY INDUSTRIES, INC. (JP) | 1997-01-02 | — | — | EP | disclosed |
| US-4464391-A | Pesticides | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137839-A1 | METHOD FOR PRODUCING (2-FORMYL-1-ALKENYL) CYCLOPROPANE COMPOUND | ACSL3, ACSL1, ARL1 | KCNH2 3454/4885KCNA3 4074/4885CA12 2854/4885 |
| US-20070197818-A1 | Method for producing (1-alkenyl) cyclopropane compound | ACSL3, ARL1, ACSL1 | KCNH2 1860/4885KCNA3 3542/4885CA12 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.